Exhibit 99.1 ProQR Announces Year End 2023 Operating and Financial Results • Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinic • Accelerated development of Axiomer™ for CNS applications via new research partnership with Rett Syndrome Research Trust • Completed divestment of sepofarsen and ultevursen ophthalmic programs to Laboratoires ...